JPH01131113A - 脳障害治療剤 - Google Patents
脳障害治療剤Info
- Publication number
- JPH01131113A JPH01131113A JP63212001A JP21200188A JPH01131113A JP H01131113 A JPH01131113 A JP H01131113A JP 63212001 A JP63212001 A JP 63212001A JP 21200188 A JP21200188 A JP 21200188A JP H01131113 A JPH01131113 A JP H01131113A
- Authority
- JP
- Japan
- Prior art keywords
- brain
- encephalopathy
- compound
- remedy
- cerebral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000014644 Brain disease Diseases 0.000 title claims abstract description 15
- 208000032274 Encephalopathy Diseases 0.000 title abstract 4
- 239000003814 drug Substances 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 230000003449 preventive effect Effects 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 11
- 206010008118 cerebral infarction Diseases 0.000 abstract description 8
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 5
- 230000002490 cerebral effect Effects 0.000 abstract description 5
- 238000002347 injection Methods 0.000 abstract description 5
- 239000007924 injection Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000000654 additive Substances 0.000 abstract description 2
- 239000011230 binding agent Substances 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 abstract description 2
- 239000007884 disintegrant Substances 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 239000006188 syrup Substances 0.000 abstract description 2
- 235000020357 syrup Nutrition 0.000 abstract description 2
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 abstract 1
- 208000026062 Tissue disease Diseases 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 229940126062 Compound A Drugs 0.000 description 8
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 8
- 230000006931 brain damage Effects 0.000 description 6
- 231100000874 brain damage Toxicity 0.000 description 6
- 208000029028 brain injury Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000004129 EU approved improving agent Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 239000000604 anti-edema agent Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960000744 vinpocetine Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63212001A JPH01131113A (ja) | 1987-08-27 | 1988-08-26 | 脳障害治療剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21380387 | 1987-08-27 | ||
| JP62-213803 | 1987-08-27 | ||
| JP63212001A JPH01131113A (ja) | 1987-08-27 | 1988-08-26 | 脳障害治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01131113A true JPH01131113A (ja) | 1989-05-24 |
| JPH0588684B2 JPH0588684B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1993-12-24 |
Family
ID=26518958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63212001A Granted JPH01131113A (ja) | 1987-08-27 | 1988-08-26 | 脳障害治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH01131113A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996033712A1 (fr) * | 1995-04-25 | 1996-10-31 | Daiichi Pharmaceutical Co., Ltd. | Remede pour lutter contre le syndrome de l'immunodeficience acquise |
| WO1998008831A1 (fr) * | 1996-08-27 | 1998-03-05 | Daiichi Pharmaceutical Co., Ltd. | Traitement preventif ou curatif de la maladie d'alzheimer |
| WO2000001380A1 (de) * | 1998-07-01 | 2000-01-13 | A. Nattermann & Cie. Gmbh | Cyclooxygenaseinhibitor |
| WO2002055076A1 (fr) * | 2001-01-04 | 2002-07-18 | Daiichi Pharmaceutical Co., Ltd. | Preparation pharmaceutique contenant de la cyclodextrine |
| US7671211B1 (en) | 1999-03-31 | 2010-03-02 | Arne Holmgren | Substrates for thioredoxin reductase |
| US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
-
1988
- 1988-08-26 JP JP63212001A patent/JPH01131113A/ja active Granted
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996033712A1 (fr) * | 1995-04-25 | 1996-10-31 | Daiichi Pharmaceutical Co., Ltd. | Remede pour lutter contre le syndrome de l'immunodeficience acquise |
| WO1998008831A1 (fr) * | 1996-08-27 | 1998-03-05 | Daiichi Pharmaceutical Co., Ltd. | Traitement preventif ou curatif de la maladie d'alzheimer |
| WO2000001380A1 (de) * | 1998-07-01 | 2000-01-13 | A. Nattermann & Cie. Gmbh | Cyclooxygenaseinhibitor |
| EP0972515A3 (de) * | 1998-07-01 | 2000-01-26 | A. Nattermann & Cie. GmbH | Cyclooxygenase-Inhibitor |
| US6495517B2 (en) | 1998-07-01 | 2002-12-17 | A. Natterman & Cie. Gmbh | Cyclooxygenase inhibitor |
| US7671211B1 (en) | 1999-03-31 | 2010-03-02 | Arne Holmgren | Substrates for thioredoxin reductase |
| WO2002055076A1 (fr) * | 2001-01-04 | 2002-07-18 | Daiichi Pharmaceutical Co., Ltd. | Preparation pharmaceutique contenant de la cyclodextrine |
| US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0588684B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1993-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100508393B1 (ko) | 신경변성질환 치료약 | |
| JPH04504726A (ja) | アナフィラキシーの遅反応性物質に対する拮抗薬としてのリポキシンａ↓４およびその誘導体の使用 | |
| JP2526059B2 (ja) | 抗潰瘍剤 | |
| JPS58185517A (ja) | 塩利尿作用を有する薬物 | |
| US3969507A (en) | Method of preventing and treating thrombosis | |
| JPH01131113A (ja) | 脳障害治療剤 | |
| WO2010034269A1 (zh) | 2,5-二羟基甲基-3,6-二甲基吡嗪及其衍生物在制药中的应用 | |
| WO1999043325A1 (fr) | Remedes preventifs ou therapeutiques contre les maladies associees a une anomalie fonctionnelle vasculaire en relation avec la resistance a l'insuline | |
| JP4486167B2 (ja) | 薬剤性腎障害の予防または治療剤 | |
| US5525605A (en) | Remedy for inflammatory intestinal diseases | |
| ES2278930T3 (es) | Uso de un derivado de la piridazinona en el tratamiento de una insuficiencia cardiaca congestiva. | |
| JPS6081127A (ja) | 食欲抑制剤 | |
| KR960014872B1 (ko) | 뇌장해 치료용 조성물 | |
| JP3130368B2 (ja) | 肝機能改善薬 | |
| EP0759298B1 (en) | Use of 4-amino-6-hydroxypyrazolo[3,4-d]pyrimidine for the manufacture of an antihypertensive agent | |
| JP2548223B2 (ja) | 腎臓疾患治療剤 | |
| JPH05504130A (ja) | 腫瘍壊死因子拮抗剤 | |
| CA1229793A (en) | Medicament for cerebral apoplexy | |
| JPS61236725A (ja) | 脳浮腫抑制剤 | |
| US4225605A (en) | Ergolene or ergoline compounds for treating congestive heart failure | |
| CA2076005A1 (en) | Use of thromboxane-a2-receptor antagonists for the prevention of reduction of degenerative process in the penile tissue | |
| JPS6245525A (ja) | 脂質低下剤 | |
| JPH01294622A (ja) | 白血球の粘着又は凝集抑制剤 | |
| JPS6345371B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPH0283321A (ja) | 膵臓疾患治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081224 Year of fee payment: 15 |